Global Solid Tumors Drugs Market Size By Type (Small Molecules, Biologics), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Solid Tumors Drugs Market was valued at USD 112.4 billion in 2023 and is expected to reach USD 189.7 billion by 2031, growing at a CAGR of 6.7% during the forecast period from 2023 to 2031. Solid tumors, which include malignancies in organs such as the lungs, breast, prostate, and colon, account for a significant share of the global cancer burden. The increasing incidence of cancer worldwide, along with the rapid advancement in targeted therapies, immunotherapy, and supportive diagnostic tools, is propelling market growth. Additionally, the expansion of healthcare infrastructure and growing investment in oncology R&D are bolstering market dynamics.

Drivers:

1. Rising Cancer Incidence Worldwide

The global rise in the number of cancer cases, especially breast, lung, colorectal, and prostate cancers, is a major market driver. According to WHO, cancer is one of the leading causes of death globally, and its increasing burden necessitates effective treatment options, stimulating demand for solid tumor drugs.

2. Advances in Targeted and Immunotherapies

The shift from conventional chemotherapies to targeted therapies and immunotherapies is transforming the treatment landscape. Drugs like checkpoint inhibitors and monoclonal antibodies are offering better efficacy with fewer side effects, driving adoption across various tumor types.

3. Expanding Access to Oncology Treatments in Emerging Markets

Improved healthcare infrastructure, government initiatives, and growing medical tourism are enhancing access to oncology treatments in emerging economies, boosting market penetration for pharmaceutical companies.

Restraints:

1. High Cost of Cancer Therapies

Advanced therapies such as immunotherapy and precision medicine come at high costs, which can limit accessibility, especially in low-income regions. This cost barrier affects treatment adherence and patient outcomes.

2. Side Effects and Drug Resistance

Some cancer therapies are associated with severe side effects or may become less effective due to resistance. This limits their long-term efficacy and can necessitate complex treatment regimens.

Opportunity:

1. Personalized Medicine and Biomarker-Driven Therapies

The growing focus on personalized medicine is unlocking new growth avenues. The development of biomarker-driven therapies and companion diagnostics enables more accurate and effective treatment planning for solid tumors.

2. Clinical Trials and Pipeline Expansion

A robust pipeline of solid tumor drugs, including next-generation immunotherapies and novel drug conjugates, presents vast opportunities. Companies investing in clinical trials and innovation are well-positioned for market leadership.

Market by System Type Insights:

By system type, Chemotherapy retained a significant share in 2023 due to its long-standing role in cancer treatment. However, the Targeted Therapy segment is projected to witness the fastest growth through 2031. The success of drugs targeting specific mutations and tumor pathways has increased their uptake. Additionally, Immunotherapy is gaining prominence as a transformative treatment, especially for melanoma, non-small cell lung cancer, and bladder cancer.

Market by End-use Insights:

Hospitals led the end-use segment in 2023, accounting for the largest share, as they serve as the primary treatment centers for cancer patients. Cancer Treatment Centers and Specialty Clinics are expected to grow rapidly due to the increasing preference for specialized and outpatient-based treatment setups, providing more personalized care and quicker access to novel therapies.

Market by Regional Insights:

North America dominated the global solid tumors drugs market in 2023, owing to its strong healthcare infrastructure, high cancer prevalence, and rapid adoption of new therapeutics. Asia-Pacific is expected to record the highest growth rate during the forecast period due to rising healthcare investments, expanding awareness, and a growing patient pool, particularly in China and India. Europe remains a significant market due to proactive healthcare policies and advanced oncology research.

Competitive Scenario:

Key players in the Global Solid Tumors Drugs Market include Roche Holding AG, Bristol-Myers Squibb, Novartis AG, Merck & Co., Pfizer Inc., AstraZeneca plc, Johnson & Johnson, Amgen Inc., Eli Lilly and Company, and Sanofi S.A. These companies are focused on innovation through R&D, clinical trials, and strategic collaborations. For instance:

In 2023, AstraZeneca expanded its oncology portfolio with FDA approval for a novel HER2-targeted therapy in breast cancer.

Merck & Co. continued its global rollout of the blockbuster checkpoint inhibitor, Keytruda, across additional solid tumor indications.

In 2024, Roche announced the acquisition of a biotech firm specializing in tumor microenvironment therapies, enhancing its position in immuno-oncology.

Scope of Work – Global Solid Tumors Drugs Market

Report Metric Details

Market Size (2023) USD 112.4 billion

Projected Market Size (2031) USD 189.7 billion

CAGR (2023–2031) 6.7%

Market Segments System Type (Chemotherapy, Targeted Therapy, Immunotherapy), End-use (Hospitals, Cancer Treatment Centers)

Growth Drivers Rising cancer incidence, targeted therapy advancements, emerging market access

Opportunities Personalized medicine, biomarker-guided therapy, clinical trial expansion

Key Market Developments:

April 2023: Novartis launched a next-generation ALK inhibitor for non-small cell lung cancer in the U.S. and EU markets.

September 2023: Eli Lilly received FDA breakthrough designation for its KRAS G12C inhibitor targeting colorectal cancer.

February 2024: Sanofi partnered with a diagnostics firm to co-develop biomarker-based therapies for pancreatic and gastric cancers.

FAQs

1